AR119715A1 - Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona - Google Patents
Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-dionaInfo
- Publication number
- AR119715A1 AR119715A1 ARP200101015A ARP200101015A AR119715A1 AR 119715 A1 AR119715 A1 AR 119715A1 AR P200101015 A ARP200101015 A AR P200101015A AR P200101015 A ARP200101015 A AR P200101015A AR 119715 A1 AR119715 A1 AR 119715A1
- Authority
- AR
- Argentina
- Prior art keywords
- dioxopiperidin
- isoindolin
- hodgkin
- dione
- lymphoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833432P | 2019-04-12 | 2019-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119715A1 true AR119715A1 (es) | 2022-01-05 |
Family
ID=70465546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101015A AR119715A1 (es) | 2019-04-12 | 2020-04-08 | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11390617B2 (https=) |
| EP (1) | EP3952880B1 (https=) |
| JP (1) | JP7562557B2 (https=) |
| KR (1) | KR102944213B1 (https=) |
| CN (1) | CN114144182B (https=) |
| AR (1) | AR119715A1 (https=) |
| AU (1) | AU2020270917B2 (https=) |
| BR (1) | BR112021020372A2 (https=) |
| CA (1) | CA3132538A1 (https=) |
| CL (1) | CL2021002651A1 (https=) |
| DK (1) | DK3952880T3 (https=) |
| ES (1) | ES3061998T3 (https=) |
| FI (1) | FI3952880T3 (https=) |
| HR (1) | HRP20251668T1 (https=) |
| IL (1) | IL287145A (https=) |
| LT (1) | LT3952880T (https=) |
| MA (1) | MA55608A (https=) |
| MX (1) | MX2021012507A (https=) |
| PT (1) | PT3952880T (https=) |
| RS (1) | RS67593B1 (https=) |
| SG (1) | SG11202111232RA (https=) |
| SI (1) | SI3952880T1 (https=) |
| SM (1) | SMT202600013T1 (https=) |
| TW (1) | TWI853014B (https=) |
| WO (1) | WO2020210418A1 (https=) |
| ZA (1) | ZA202107668B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| AU2020369497B2 (en) | 2019-10-21 | 2026-02-05 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| US11666579B2 (en) * | 2019-10-21 | 2023-06-06 | Celgene Corporation | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| CA3154890A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion |
| JP7676375B2 (ja) | 2019-10-21 | 2025-05-14 | セルジーン コーポレーション | （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンおよびその塩を含む固形体、並びにそれを含む組成物およびそれを使用する方法 |
| WO2021080955A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| CA3154908A1 (en) | 2019-10-21 | 2021-04-29 | Sreenivas S. Bhat | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam |
| AU2022252220A1 (en) * | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma |
| JP2024515108A (ja) * | 2021-04-21 | 2024-04-04 | セルジーン コーポレーション | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用して非ホジキンリンパ腫を治療する方法 |
| EP4326266A1 (en) * | 2021-04-21 | 2024-02-28 | Celgene Corporation | Methods of treating b-cell lymphoma using combination therapy |
| WO2022271557A1 (en) | 2021-06-21 | 2022-12-29 | Celgene Corporation | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002253795B2 (en) | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
| PL2076260T3 (pl) * | 2006-09-15 | 2011-08-31 | Celgene Corp | Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| BR112015002285B1 (pt) * | 2012-08-09 | 2022-05-10 | Celgene Corporation | Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer |
| HK1214552A1 (zh) | 2012-11-05 | 2016-07-29 | 细胞基因公司 | 在腎損傷的受試者中用泊馬度胺治療癌症 |
| CN105246480A (zh) * | 2013-04-02 | 2016-01-13 | 细胞基因公司 | 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 |
| CN111205268B (zh) * | 2014-10-30 | 2021-01-26 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| CN118344338A (zh) * | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
-
2020
- 2020-04-08 AR ARP200101015A patent/AR119715A1/es unknown
- 2020-04-09 BR BR112021020372A patent/BR112021020372A2/pt not_active Application Discontinuation
- 2020-04-09 SM SM20260013T patent/SMT202600013T1/it unknown
- 2020-04-09 JP JP2021559978A patent/JP7562557B2/ja active Active
- 2020-04-09 US US16/844,407 patent/US11390617B2/en active Active
- 2020-04-09 CN CN202080043197.0A patent/CN114144182B/zh active Active
- 2020-04-09 WO PCT/US2020/027358 patent/WO2020210418A1/en not_active Ceased
- 2020-04-09 AU AU2020270917A patent/AU2020270917B2/en active Active
- 2020-04-09 SG SG11202111232RA patent/SG11202111232RA/en unknown
- 2020-04-09 RS RS20251313A patent/RS67593B1/sr unknown
- 2020-04-09 TW TW109112033A patent/TWI853014B/zh active
- 2020-04-09 FI FIEP20722180.5T patent/FI3952880T3/fi active
- 2020-04-09 KR KR1020217036544A patent/KR102944213B1/ko active Active
- 2020-04-09 SI SI202030706T patent/SI3952880T1/sl unknown
- 2020-04-09 CA CA3132538A patent/CA3132538A1/en active Pending
- 2020-04-09 LT LTEPPCT/US2020/027358T patent/LT3952880T/lt unknown
- 2020-04-09 ES ES20722180T patent/ES3061998T3/es active Active
- 2020-04-09 PT PT207221805T patent/PT3952880T/pt unknown
- 2020-04-09 MA MA055608A patent/MA55608A/fr unknown
- 2020-04-09 DK DK20722180.5T patent/DK3952880T3/da active
- 2020-04-09 MX MX2021012507A patent/MX2021012507A/es unknown
- 2020-04-09 EP EP20722180.5A patent/EP3952880B1/en active Active
- 2020-04-09 HR HRP20251668TT patent/HRP20251668T1/hr unknown
-
2021
- 2021-10-08 CL CL2021002651A patent/CL2021002651A1/es unknown
- 2021-10-10 IL IL287145A patent/IL287145A/en unknown
- 2021-10-11 ZA ZA2021/07668A patent/ZA202107668B/en unknown
-
2022
- 2022-06-24 US US17/848,976 patent/US12103923B2/en active Active
-
2024
- 2024-08-09 US US18/799,483 patent/US20240400548A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119715A1 (es) | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| PE20071184A1 (es) | Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo | |
| MX2021007925A (es) | Inhibidores irreversibles de la interaccion menina-mll. | |
| ZA201903125B (en) | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors | |
| MX2023008453A (es) | Metodos de tratamiento para el abuso de sustancias. | |
| MX2019003098A (es) | Composicion farmaceutica. | |
| DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
| ECSP056229A (es) | Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| SG11201811697SA (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| EA200401160A1 (ru) | Производные тиазола и оксазола, которые модулируют активность ppar | |
| UY33397A (es) | Forma sólida de un naftaleno carboxamida | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| GT200600359A (es) | Fungicidal n-[2-(haloalkoxy)phenyl]heteroarylcarboxamides | |
| MX2022004727A (es) | Metodos de tratamiento de la leucemia linfocitica cronica con 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)benzil)amino)isoindolina-1,3-diona. | |
| CL2018001830A1 (es) | Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| MX2022004683A (es) | Metodos de tratamiento de neoplasias hematologicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona. | |
| DOP2018000134A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| EP4545095A3 (en) | Pharmaceutical composition containing heterocyclidene acetamide derivative for use in treating dry eye | |
| UA101961C2 (xx) | Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида | |
| AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical | |
| MX2023012294A (es) | Metodos de tratamiento del linfoma no hodgkin mediante el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il) metil)benzil)amino)isoindolin-1,3-diona. |